Our top pick for
Building a portfolio
Genetron Holdings Limited is a diagnostics & research business based in the US. Genetron shares (GTH) are listed on the NASDAQ and all prices are listed in US Dollars. Genetron employs 799 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$9.03 - $31.54|
|50-day moving average||$22.03|
|200-day moving average||$17.51|
|Wall St. target price||$25.52|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$424.5 million|
|Gross profit TTM||$260.2 million|
|Return on assets TTM||-12.56%|
|Return on equity TTM||-2433.48%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
There are currently 446,959 Genetron shares held short by investors – that's known as Genetron's "short interest". This figure is 62.6% up from 274,936 last month.
There are a few different ways that this level of interest in shorting Genetron shares can be evaluated.
Genetron's "short interest ratio" (SIR) is the quantity of Genetron shares currently shorted divided by the average quantity of Genetron shares traded daily (recently around 417718.69158879). Genetron's SIR currently stands at 1.07. In other words for every 100,000 Genetron shares traded daily on the market, roughly 1070 shares are currently held short.
However Genetron's short interest can also be evaluated against the total number of Genetron shares, or, against the total number of tradable Genetron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genetron's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Genetron shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genetron shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genetron.
Find out more about how you can short Genetron stock.
We're not expecting Genetron to pay a dividend over the next 12 months.
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.